• Baxa (Englewood, Colorado) reported the release of upgrades to its IntelliFlowRx workflow management system. IntelliFlowRx is designed to improve safety and accuracy in pharmacy-based IV admixture preparation. The system also streamlines compliance with sterile preparation regulatory steps while improving visibility to and oversight of IV room operations. The latest upgrade adds a number of features to the IntelliFlowRx System, including the ability to define specific workflows for different types of doses within the health-system pharmacy, i.e., preparation modes and drug delivery routes - enabling customers to prepare oral liquid doses using IntelliFlowRx.

• Calypso Medical Technologies (Seattle) reported the publication of three new studies investigating the role of the Calypso 4D Localization System in guiding immediate adjustments to radiation delivery in response to tumor motion, a concept known as real-time adaptive radiation treatment. The first study demonstrates how the Calypso System is integrated with the linear accelerator - the equipment used to deliver radiation to cancerous tumors - to gate the radiation beam when the tumor motion exceeded certain thresholds. For the first time, the ability to automatically turn the beam on and off, termed "gating," has been demonstrated utilizing internal information that reflects how the tumor is moving rather than relying on external markers. Gating the beam based on actual tumor motion improves the quality of treatment that the patient receives. The other studies highlight that Calypso System data can be used to adapt treatment by guiding the multi-leaf collimator - the part of the linear accelerator used to shape the radiation beam - thereby moving it in real time.

• Rules-Based Medicine (RBM; Austin, Texas) reported the availability of a collection of quantitative immunoassays for use in advancing safety, efficacy and efficiency in drug and diagnostic development. The new service, DiscoveryMAP v 1.0, offers coverage of most physiologically relevant pathways, providing biological information and leads for further study. DiscoveryMAP samples are processed in RBM's CLIA-certified lab using proprietary reagents and software to give the most accurate and reproducible protein measurements. Multiplexing allows all of these assays to be processed from a 500 microliter sample of serum or plasma, compared with single-plex platforms, such as ELISA, which would require upwards of 10 to 15 milliliters of sample.